AxoGen, Inc. (AXGN) Stock AnalysisAXGNAxoGen, Inc.

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

AxoGen Inc is currently priced at $34.62, with a forward P/E of 102.04 indicating high future earnings expectations. However, the RSI is at a low 22.42, suggesting the stock is oversold and may rebound. The primary risk is the significant insider selling, which has increased by 768.09% over the last month, indicating potential lack of confidence from insiders.

6 analysts cover AXGN: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.80.